Analysis Tools|
Allele Symbol Allele Name Allele ID |
Otulintm1c(EUCOMM)Hmgu targeted mutation 1c, Helmholtz Zentrum Muenchen GmbH MGI:6449230 |
| Summary |
7 genotypes |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• normal circulating inflammatory cytokine and chemokine levels in most mice
|
|
• delineated inflamed skin lesions from age 6 weeks in some mice
|
| N |
• no skin lesions and normal epidermal thickness in most mice
|
|
• delineated inflamed skin lesions from age 6 weeks in some mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• normal circulating inflammatory cytokine and chemokine levels
|
| N |
• no dermatitis and normal epidermal thickness up to age older than 40 weeks
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• delineated inflamed skin lesions on back
|
|
• delineated inflamed skin lesions on back
|
|
• delineated inflamed skin lesions on back
|
|
• verrucous carcinomas on back skin
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• normal circulating inflammatory cytokine levels
|
| N |
• no skin lesions and normal epidermal thickness
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• delineated inflamed skin lesions on back
• no skin lesions in tail
|
| N |
• no skin lesions and normal epidermal thickness in tail
|
|
• delineated inflamed skin lesions on back
• no skin lesions in tail
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• increased hair follicle stem cell (HFSC) and interfollicular epidermis (IFE) cell apoptosis
|
|
• in both skin lesions and non-lesional skin at age 7 weeks
|
|
• hyperproliferation
• accelerated wound closure at day 2 and 4 post-wounding
• decelerated wound closure at day 8 post-wounding
|
|
• hypersebacea at age 7 weeks
|
|
• at wound sites after completion of re-epithelialization
|
|
• of back and tail skin lesions at age 7 weeks
• normal in non-lesional skin
|
|
• delineated inflamed skin lesions on back and tail from age P6 onwards
• infiltration of immune cells into lesional skin
|
|
• of back and tail skin lesions at age 7 weeks
• normal epidermal thickness of non-lesional skin
|
|
• tumor-like lesions at wound sites after completion of re-epithelialization
|
|
• delineated inflamed skin lesions on back and tail from age P6 onwards
|
|
• verrucous carcinoma developed from back and tail skin lesions
|
|
• verrucous carcinoma developed from back and tail skin lesions
|
|
• delineated inflamed skin lesions on back and tail from age P6 onwards
• infiltration of immune cells into lesional skin
|
|
• increased hair follicle stem cell (HFSC) and interfollicular epidermis (IFE) cell apoptosis
|
|
• in both skin lesions and non-lesional skin at age 7 weeks
|
|
• hyperproliferation
• accelerated wound closure at day 2 and 4 post-wounding
• decelerated wound closure at day 8 post-wounding
|
|
• hypersebacea at age 7 weeks
|
|
• of back and tail skin lesions at age 7 weeks
• normal in non-lesional skin
|
|
• at wound sites after completion of re-epithelialization
|
| N |
• born at normal Mendelian ratios
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 09/30/2025 MGI 6.24 |
|
|
|
||
